656 filings
10-Q
2024 Q1
SRPT
Sarepta Therapeutics Inc
Quarterly report
1 May 24
4:01pm
DEF 14A
SRPT
Sarepta Therapeutics Inc
Definitive proxy
24 Apr 24
4:05pm
ARS
2023 FY
SRPT
Sarepta Therapeutics Inc
24 Apr 24
Annual report to shareholders
4:02pm
DEFA14A
SRPT
Sarepta Therapeutics Inc
24 Apr 24
Additional proxy soliciting materials
4:01pm
S-8 POS
SRPT
Sarepta Therapeutics Inc
28 Mar 24
Registration of securities for employees (post-effective amendment)
4:16pm
S-8 POS
pmjephsmlol hdam3
28 Mar 24
Registration of securities for employees (post-effective amendment)
4:15pm
S-8 POS
f6wfmkyp7 6y0
28 Mar 24
Registration of securities for employees (post-effective amendment)
4:14pm
S-8 POS
j1bqil mkw
28 Mar 24
Registration of securities for employees (post-effective amendment)
4:12pm
8-K
3ufkttnb 03an
8 Jan 24
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
12:08pm
S-8
qdokf52p081ou508
2 Aug 23
Registration of securities for employees
4:19pm
8-K
e7mm4
22 Jun 23
Regulation FD Disclosure
4:49pm
8-K
73jbh1iaem2i53tg4
22 Jun 23
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
12:00am
8-K
hogbkrknsvqi82
9 Jun 23
Departure of Directors or Certain Officers
4:29pm
DEFA14A
1larsqz2 fh3j
24 Apr 23
Additional proxy soliciting materials
4:16pm
ARS
b1zrf70r1zn jqvq1f2w
24 Apr 23
Annual report to shareholders
4:10pm